Actively Recruiting
Phase 2 Study of Adding Local Ablative Therapy to Ongoing Systemic Treatment for Oligo-Progressive Gastrointestinal Cancers
Led by University of California, Davis · Updated on 2026-07-02
300
Participants Needed
1
Research Sites
301 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the clinical benefit of continuing systemic therapy combined with locally ablative therapies for patients with oligo-progressive solid tumors, focusing on gastrointestinal cancers. This phase 2 pragmatic study aims to assess disease control at 3 months after local ablative treatment, with the primary goal of maintaining systemic cancer therapy without changes or discontinuation. The study is conducted at a single site and sponsored by the University of California, Davis. Participants receive locally ablative therapy, which may include stereotactic ablative radiotherapy SABR or interventional radiology IR ablation therapy, chosen by the treating radiation oncologist or interventional radiologist. This ablative therapy is added to their ongoing systemic cancer treatment. Participants will be followed for up to 5 years after receiving the ablative local therapy to monitor outcomes and safety. During the study, participants will be monitored for disease control at 3 months, adverse events related to ablative therapy up to 2 years, median overall survival up to 5 years, and time to treatment failure within a year. Assessments include clinical evaluations and standard care procedures. The study tracks how well participants tolerate the combined treatment and measures how long systemic therapy can be continued without change.
CONDITIONS
Brief Title
Locally ablatIVe thErapy for oLigo-progressive gastrOintestiNal maliGnancies (LIVELONG)
Research Team
O
Office of Clinical Research
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here